Harnessing the Power of Heat to Fight Cancer

The Thermofield® hyperthermia deep tissue heating system, exclusively from Midmark, represents a significant advance in devices used to treat cancerous superficial tumors. Never before has a device been available to veterinarians that is as practical and simple to use to help make existing cancer treatments more effective.

Contact us to learn more

Powerful Hyperthermia Technology

In a Portable, Safe and Cost-Effective Package

his is the first compact and easy-to-use device that provides noninvasive deep tissue heating for superficial tumors residing within 4 cm of the skin’s surface. This technology exceeds the performance specifications of devices 10 times larger and more expensive currently approved to treat superficial tumors in people.

The Thermofield® hyperthermia system overcomes many obstacles that have limited the use of hyperthermia as a cancer therapy. It creates a structured electromagnetic field inside the body that gently heats cancerous tissue up to 4C greater than surface temperatures, achieving therapeutic temperatures. The conformal applicators generate consistent heating patterns and use integrated thermocouple sensors to measure surface temperatures, diminishing the risk of surface burns and thermal damage to collateral tissue.

Thermofield® is proven to elevate cancer treatment in the following ways:

  • Improves Chemotherapy Efficacy up to 500%
  • Improves Radiation Efficacy up to 300%
  • Effectively Palliates Cancer Pain
  • Improves Tumor Control and Survival Times

Hyperthermia mechanisms of action:

  • Triggers release of immune system components that fight cancer
  • Helps immune system better recognize cancer cells through the expression of Heat Shock Proteins (HSPs)
  • Increases blood flow to deliver more drug to the tumor
  • Sensitizes cancer cells to radiation
  • Damages tumor vasculature and kills cancer cells at higher temps
  • Inhibits cancer cell’s normal DNA repair mechanism
  • Mitigates pain, drug free

Skin Sparing Applicator Technology

Minimizes the Risk of Surface Burns

The applicator design of the Thermofield® hyperthermia system minimizes the risk of surface burns relative to conventional hyperthermia applicator technology. When electromagnetic waves strike the body, they tend to heat the skin excessively due to the boundary condition that exists between the skin and the air. The Thermofield® applicator creates a strong, time-variable electromagnetic field that is projected into the tissue, sparing the skin by circumventing the strong field interaction at the surface and dumping energy directly into the subdermal tissue.

Conformal Multilayer Applicator:

  • Flexible to conform to the irregular contours of the body
  • Accommodates large superficial tumors in a variety of anatomical locations
  • Quickly establishes a radio frequency (RF) electromagnetic (EM) field inside tissue that can deposit enough energy to reach targeted surface temperatures (39°C-42° C) in approximately 10 minutes
  • Easy to apply and can be sanitized between uses

Computed SAR valued in 10 cm of muscle

Deep Non-Invasive Heating Pattern

The Thermofield applicator operates at 10, 20, or 30 watts and achieves a well-structured deep-heating pattern.

Top View

Shows applicator outline, slot aperture, specific absorption rate (SAR) at depth of 1cm

Side and End View

Taken at respective center planes and presented for a depth of 0 to 7.5 cm

SARs at 50% and 25% of the 1 cm median value are evidenced at depths of 3 and 4 cm, respectively.

Clinical Outcomes

Thermochemotherapy tested in over 200 dogs

With Advanced Stage Solid Tumors During a 4 Year University Evaluation

To date, cancer researchers have successfully used Thermofield® technology in dogs, cats, and horses. Treatments involve a combination of heat + chemotherapy. Thermofield® hyperthermia therapy was given twice weekly and was monitored using the thermo-sensors designed within the applicator and verified using invasive temperature probes. Target skin temperatures ranged from 41-43°C (107-113°F) and were maintained for 45 minutes pretreatment. Clinical activity of combination thermochemotherapy was assessed in a population of canines with loco-regionally advanced (≥T2) superficial solid tumors. This population included 37 dogs diagnosed with head and neck carcinomas, 42 dogs diagnosed with head and neck sarcomas, 18 dogs with carcinomas of other anatomic locations, 10 dogs with primary bone tumors, and >90 dogs with cutaneous and subcutaneous sarcomas of varying anatomic locations. Carboplatin chemotherapy was the drug of choice, selected on the basis of tumor histology and previous literature suggesting a synergistic interaction between platinum drugs and hyperthermia.
In each dog a target lesion, ranging from 2-6cm in diameter, was selected for thermal treatments and outcome determinations. The outcome data collected included: toxicity data, time to response, objective response, progression-free interval, and (where applicable) a description of palliative benefits. Overall, incidence of Grade III or higher toxicity in any category was <3%. Median time to response for was three weeks, and the overall objective response was 65%. Median progression-free interval for target lesions in dogs with head and neck cancer was 7.3 months, a time significantly longer than that reported in dogs treated with chemotherapy alone for either oral or nasal tumors (median 2 months and 5 months, respectively). Palliative benefits including pain mitigation and improvements in quality of life scores were evaluated in all dogs diagnosed with primary bone sarcomas. Using force-plate analysis, pain mitigation was documented in 70% of treated dogs, and all owners reported improvement in quality-of-life scores.


Want to learn more?

Click the button below and fill out a quick form to get in contact with a Midmark representative.

Contact Us

Better Patient Care. Better Business™

Midmark Corporation, Dayton Ohio